Unmet medical needs and target patients with severe heart failure and ischemic heart disease
First written in FY2023. . Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026Target-patient data updatedAnnual report
「According to the 2023 Nationwide Patient Survey published by the Ministry of Health, Labour and Welfare, the number of patients with ischemic cardiomyopathy in Japan was 3,000 annually. As of the end of March 2026, 789 people were registered as wishing to receive a heart transplant. Taking these figures into account, we believe that a considerable number of patients are potential targets for our products.」
The company disclosed updated target-patient data of 3,000 annual ischemic cardiomyopathy patients and 789 registered heart-transplant candidates. - FY2025Target-patient data updatedAnnual report
「According to the Japan Organ Transplant Network, 813 people were registered as wishing to receive a heart transplant as of the end of March 2025. Data on holders of certificates for specified medical expenses indicate that there were 18,108 DCM patients as of the end of FY2023.」
The company disclosed updated target-patient data of 813 registered heart-transplant candidates and 18,108 DCM patients. - FY2024Additional target-patient dataAnnual report
「According to the Japan Organ Transplant Network, 859 people were registered as wishing to receive a heart transplant as of the end of March 2024. Taking this into account, we believe that a considerable number of patients are potential targets for our products. Regarding the number of patients with dilated cardiomyopathy, for which we aim to add an indication, data published by the Intractable Disease Information Center operated by the Intractable Disease Research Foundation show that there were 18,234 holders of certificates for specified medical expenses as of the end of FY2022.」
The company newly disclosed target-patient data of 859 registered heart-transplant candidates and 18,234 DCM patients. - FY2023First statedAnnual report
「Our human iPS cell-derived cardiomyocyte sheet is intended to halt disease progression in patients for whom improvement cannot be expected from standard medical treatment until they reach a condition requiring an artificial heart-assist device or heart transplantation. It addresses unmet medical needs—medical needs for diseases for which no effective treatment is available—that existing products cannot cover.」
The company estimated the annual number of target patients in Japan at approximately 5,000 and the number of NYHA Class III B patients at 130,000, and also disclosed patient estimates for the United States and the world.